Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 3/20 | 0.64 |
| ▸ | HHAT | Q5VTY9 | 3/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.45 |
| ▸ | NCOR2 | Q9Y618 | 2/20 | 0.45 |
| ▸ | TRPM8 | Q7Z2W7 | 3/20 | 0.43 |
| ▸ | DRD1 | P21728 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8214335 | 1.00 | PRCP (0.64) | PRCPHHATCYP2D6HDAC8HDAC3 | |
| SCHEMBL12240069 | 0.85 | PRCP (0.61) | PRCPHHATCYP2D6HDAC8HDAC3 | |
| SCHEMBL8206740 | 0.83 | PRCP (0.50) | PRCPHHATCYP2D6 | |
| SCHEMBL21236187 | 0.80 | PRCP (0.45) | PRCPDRD1 | |
| SCHEMBL12226743 | 0.80 | PRCP (0.45) | PRCPDRD1 | |
| SCHEMBL8027055 | 0.79 | TRPV1 (0.64) | CYP2D6 | |
| SCHEMBL8415128 | 0.78 | PRCP (1.00) | PRCPHHATHDAC8HDAC3HDAC1 | |
| SCHEMBL13928812 | 0.78 | PRCP (1.00) | PRCPHHATHDAC8HDAC3HDAC1 | |
| SCHEMBL28866519 | 0.77 | PRCP (0.42) | PRCPDRD1 | |
| SCHEMBL4737687 | 0.77 | PRCP (0.45) | PRCPHHAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10787446-B2 | Therapeutic compounds and methods of use thereof | GENENTECH, INC. (US) | 2020-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10787446-B2 | Therapeutic compounds and methods of use thereof | AVPR1B, C3AR1, RHEB | PRCP 1092/4885HHAT 4196/4885CYP2D6 1719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.